This website uses first-party and third-party cookies to enhance our services and show you information related to your preferences by analysing your browsing habits. By continuing to browse our website you accept our use of cookies. You can change the settings or get more information by visiting our Cookies Policy.

1. Identification of the website owner

 

GRUPO FERRER INTERNACIONAL, SA

A-61738993

Av. Diagonal 549, 5ª planta, 08029, Barcelona (Spain)

Registered in the Barcelona Company Register, volume 24901, folio 001, sheet number B-78991, entry 34

Telephone: 936 003 700

 

2. User acceptance

 

These Terms of Use regulate access to and use of the website [insert web page address] which FERRER provides to Internet users.

GRUPO FERRER INTERNACIONAL, SA may offer services through the website that may be subject to some specific conditions about which the user will be informed in each case.

By entering and browsing this website you unreservedly accept these Terms of Use.

 

3. Access to the website

 

This website is aimed exclusively at users over the age of 18. Generally prior registration as a user is not required to access and use the website, although it is necessary to register to use some of its services and content.

User data obtained through subscription or registration are protected by passwords chosen by the user. The user agrees to keep their password secret and protect it from unauthorised use by third parties. The User will notify GRUPO FERRER INTERNACIONAL, SA immediately of any non-consensual use of their account or any security violation related to the website service of which they become aware.

GRUPO FERRER INTERNACIONAL, SA has in place the technical and organisational measures required to ensure the protection of personal data and avoid its alteration, loss, processing and/or unauthorised access given the state of the art, the nature of the data stored and the risks they are exposed to in accordance with the provisions of Spanish data protection legislation. 

GRUPO FERRER INTERNACIONAL, SA is not liable to users for any disclosure of their personal data to third parties that is not due to causes directly attributable to GRUPO FERRER INTERNACIONAL, SA or for the use made of such data by third parties unrelated to GRUPO FERRER INTERNACIONAL, SA.  

 

4. Proper use of the website

 

The user agrees to use the website, its contents and services in accordance with the law, these conditions, morality and public order. Similarly, the user agrees not to use the website or the services provided through it for purposes that are unlawful or contrary to the contents of these terms of use, harmful to the interests or rights of third parties, or which may in any way damage, disable or impair the website or its services or prevent normal use of the website by other users.

The user also expressly agrees not to destroy, alter, disable or otherwise damage the data, programs or electronic documents contained on the website.

The user agrees not to hinder the access of other users to the service by mass consumption of the computing resources through which GRUPO FERRER INTERNACIONAL, SA provides the service, or to perform actions that damage, interrupt or cause errors in these systems.

The user agrees not to enter programs, viruses, macros, applets, ActiveX controls or any other logical device or character sequence that causes or is likely to cause any kind of alteration to the computer systems of GRUPO FERRER INTERNACIONAL, SA or third parties.

 

 

5. Advertising

 

Part of the website may contain advertising or be sponsored. Advertisers and sponsors are solely responsible for ensuring that material submitted for inclusion on the website complies with laws that may be applicable in each case. 

GRUPO FERRER INTERNACIONAL, SA will not be liable for any error, inaccuracy or irregularity that may be included in advertising or sponsor content. In all cases, for any complaints related to advertising content contained on this website, please contact the following email address: lopd@ ferrer.com.

 

 

6. Third-party links 

 

These Terms of Use refer only to the website and content of GRUPO FERRER INTERNACIONAL, SA. They do not apply to the links or to the websites of third parties accessible through the website. 

The destinations of these links are not under the control of GRUPO FERRER INTERNACIONAL, SA and hence GRUPO FERRER INTERNACIONAL, SA is not responsible for the content of any of the websites which are the destination of a link, or for any link contained on a website that is reached from the website of GRUPO FERRER INTERNACIONAL SA, or for any changes or updates to such sites. 

These links are provided solely to inform the user about the existence of other sources of information about a particular topic, and the inclusion of any link does not imply endorsement of the linked website by GRUPO FERRER INTERNACIONAL, SA.  

 

7. Intellectual and industrial property

 

All the contents of the website, unless otherwise indicated, are the exclusive property of GRUPO FERRER INTERNACIONAL, SA and, by way of example but not limitation, include the graphic design, source code, logos, text, graphics, illustrations, photographs and other elements that appear on the website.

Similarly, all trade names, trademarks or distinctive signs of any kind on the website are protected by law. 

GRUPO FERRER INTERNACIONAL, SA does not grant the user any licence or authorisation for personal use of its intellectual and industrial property or any other right related to its website and the services offered on it.

Consequently the user acknowledges that the reproduction, distribution, commercialisation, transformation and in general any other form of exploitation by any means of all or part of the contents of this website constitutes an infringement of the intellectual and/or industrial property rights of GRUPO FERRER INTERNACIONAL, SA or the holder thereof.

 

 

8. Applicable law and jurisdiction

 

In the event of any conflict or dispute in the interpretation or application of these Terms of Use, the matter will be heard by the courts specified by applicable jurisdiction regulations, and as they involve final consumers it will be the court for the place of performance of the obligation or for the address of the consumer.

This is without prejudice to the right of the user to turn to the Consumer Arbitration Board for their area.

In the case that it concerns a company, both parties hereby expressly waive any other venue to which they may be entitled and submit to the courts of Barcelona (Spain).”

 

9. Amendment of the Terms of Use

 

FERRER reserves the right to change or update the Disclaimer at any time so users are advised to read it on a regular basis.

Tasectan ®

PUBLICATION

 

MAGAZINE/CONGRESS

     
Allegrini A. & Constantini M., “Gelatine Tannate for the treatment of Acute Diarrhoea in Adults”   J Gastroint Dig Syst 2012, 2:3.
     
Guzganu I., “Severe Diarrhea in a 4-month-old baby girl with acute gastroenteritis: a case report and review of the literature”

 

Case Reports in Gastrointestinal Medicine, Volume 2012.
     
Allegrini A. et al. “Tasectan (gelatine tannate) for the treatment of acute gastroenteritis in children: Preliminary results from a study conducted to evaluate its efficacy and safety”   Poster published at the 39th annual paediatric Belgium society congress, Brussels, March 2011
     
Carretero et al, “A comparative analysis of response to ORS (oral rehydration solution) vs. ORS + gelatine tannate in two cohorts of paediatric patients with acute diarrhoea”

 

Rev. Esp. Enferm. Dig, Vol.101 Nº1, pp. 41-48, 2009.
     
Durban Reguera F. et al, “Prospective Observational Study on Infants and children with Acute Diarrhoea treated with gelatine tannate”.

 

Poster Published at “Semana de las Enfermedades Digestivas” in Madrid (Spain), June 2007.
     
Durban Reguera F. et al, “Prospective Observational Study on Adults with Acute Diarrhoea treated with gelatine tannate”.

 

Poster Published at “Semana de las Enfermedades Digestivas” in Madrid (Spain), June 2007.
     

Freli V. et al, "New insights into the mechanism of action of gelatine tannate for acute diarrhoea. Part 1: film-forming effect".

 

Presented as oral communication at the 33rd edition of the Congress from the Groupe Francophone d'Hépato-Gastroentérologie et Nutrition Pédiatriques in Nantes, France, on 30th March 2012.
     
De Servi B, et al., “New insights into the mechanism of action of gelatine tannate for acute diarrhoea. Part 2: antibacterial activity”.

 

Presented as oral communication at the 33rd edition of the Congress from the Groupe Francophone d'Hépato-Gastroentérologie et Nutrition Pédiatriques in Nantes, France, on 30th March 2012.
     
L. Bueno et al, “Undissociated Gelatine Tannate reduces intestinal leakiness and mucosa inflammation by forming a protective biofilm: results from in- vitro and in-vivo studies”

 

UEG Journal - United European Gastroenterology Journal, Oct.2013: Vol. 1, Supl. 1; ISSN 2050-6406 (print) ISSN 2050-6414 (online).
     

XilaPlus®

PUBLICATION

 

MAGAZINE/CONGRESS

     
Lucio Gnessi, Vladimir Bacarea, Marius Marusteri and Núria Piqué. Xyloglucan for the treatment of acute diarrhea: results of a randomized, controlled, open-label, parallel group, multicentre, national clinical trial.   BMC Gastroenterology (2015) 15:153
     
Lucio Gnessi, Xavier Llop, Núria Piqué. Xyloglucan for the treatment of acute diarrhea: results of a randomized, controlled, open-label, parallel group, multicentre, national clinical trial.

 

23rd UEG WEEK BARCELONA. October 24-28 2015
     
Catalin Pleasea Condratovici, Vladimir C. Bacârea, Núria Piqué. Xyloglucan for the treatment of acute gastroenteritis in children: results of a randomized, controlled, clinical trial.

 

Gastroenterology Research and Practice. April 2016
     
Catalin Pleasea Condratovici, Xavier Llop, Núria Piqué, Vladimir Bacarea. Xyloglucan for the treatment of acute gastroenteritis in children: results of a randomized, controlled, open-label, parallel group, multicentre, national clinical trial.   23rd UEG WEEK BARCELONA. October 24-28 2015
     

Utipro Plus®

PUBLICATION

 

MAGAZINE/CONGRESS

     
Alejandro García-Larrosa and Octavian Alexe. Efficacy and Safety of a Medical Device versus Placebo in the Early Treatment of Patients with Symptoms of Urinary Tract Infection: A Randomized Controlled Trial.   Clin Microbiol 2016, 5:1
     
Nicola Salvatorelli, Alejandro García-Larrosa, Alessandro Allegrini, Daniele Pavone. A New Approach to the Treatment of Uncomplicated Cystitis: Results of a Randomized Placebo-Controlled Clinical Trial.   Urol Int. Published online: April 8, 2016
     
Barbara de Servi1, Francesco Ranzini1 & Nuria Piqué*. Effect of Utipro® (containing gelatin- xyloglucan) against Escherichia coli invasion of intestinal epithelial cells: results of an in vitro study.

 

Future Microbiology. Posted online on March 29, 2016.
     
Hélène Eutamene, Cherryl Harkat, Valérie Bezirard, Vassilia Theodorou. Undissociated gelatin tannate and xyloglucan prevent gut leakiness and mucosal inflammation induced by LPS: Insights in the Mechanism of action.

 

UEG Week. Vienna October 2016.
     
Maïwenn Olier, Soraya Sekkal, Cherryl Harkat, Hélène Eutamène, Vassilia Theodorou, Lionel Bueno. In vivo evaluation of properties of a new medical device against intestinal commensals with uropathogenic potential   American Gastroenterology association congress (May 2016)
     
Alex García-Larrosa. Utipro® un nuevo tratamiento efectivo contra los síntomas de cisititis aguda.

 

Spanish national Urology Congress. Tenerife 2014.
     
Alex García-Larrosa, Xavier Llop. Utipro® is more effective than placebo in reducing recurrent cystitis. Preliminary results.

 

XXI Congresso nazionale AURO II. Roma 2014
     

Gelsectan®

PUBLICATION

 

MAGAZINE/CONGRESS

     
Octavian Alexea, Vlad Bacarea and Nuria Pique. The combination of oligo- and polysaccharides and reticulated protein for the control of symptoms in patients with irritable bowel syndrome: Results of a randomised, placebo-controlled, double-blind, parallel group, multicentre clinical trial.   United European Gastroenterology Journal. June 2016 vol. no. 3 455-465

http://ueg.sagepub.com/content/4/3/455.full.pdf
     
       
This area contains information intended exclusively for health professionals authorized to prescribe or dispense pharmaceutical products.
   
Calle Consejo de Ciento, 333
08007 Barcelona, Spain

Contact us

info@noventure.com
NOVENTURE S.L.
Tel: +34.93.205.27.18